Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?

被引：1
|
作者：
Abdallah, Mostafa [1 ]
Reichard, Kaaren [1 ]
Gangat, Naseema [1 ]
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Rochester, MN 55905 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
TP53; MUTATIONS; PREVALENCE;
D O I：
10.1038/s41408-024-01027-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
    Washington, Nyomi R.
    Shippey, Eugen A.
    Osswald, Michael
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [32] Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era
    Reagan, John L.
    Ollila, Thomas
    Dubielecka, Patrycja M.
    Olszewski, Adam J.
    BLOOD, 2016, 128 (22)
  • [33] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [34] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
  • [35] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [36] Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
    Feurstein, Simone
    Thomay, Kathrin
    Hofmann, Winfried
    Buesche, Guntram
    Kreipe, Hans
    Thol, Felicitas
    Heuser, Michael
    Ganser, Arnold
    Schlegelberger, Brigitte
    Goehring, Gudrun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
  • [37] What lies beyond del(5q) in myelodysplastic syndrome?
    Adema, Vera
    Bejar, Rafael
    HAEMATOLOGICA, 2013, 98 (12) : 1819 - 1821
  • [38] Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?
    Donat Dürr
    Raffaele Daniele Siciliano
    Yvonne Hummel
    Alix O’Meara
    Anita Hirschi
    Roger Burkhard
    Hanspeter Honegger
    Annals of Hematology, 2010, 89 : 105 - 106
  • [39] Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)
    Zemanova, Zuzana
    Michalova, Kyra
    Brezinova, Jana
    Svobodova, Karla
    Lhotska, Halka
    Sarova, Iveta
    Lizcova, Libuse
    Izakova, Silvia
    Ransdorfova, Sarka
    Pavlistova, Lenka
    Berkova, Adela
    Skipalova, Karolina
    Belickova, Monika
    Siskova, Magda
    Neuwirtova, Radana
    Cermak, Jaroslav
    Stopka, Tomas
    Jonasova, Anna
    BLOOD, 2016, 128 (22)
  • [40] Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
    Lode, Laurence
    Menard, Audrey
    Flet, Laurent
    Richebourg, Steven
    Loirat, Marion
    Eveillard, Marion
    Le Bris, Yannick
    Godon, Catherine
    Theisen, Olivier
    Gagez, Anne-Laure
    Cartron, Guillaume
    Commes-Maerten, Therese
    Villemagne, Bruno
    Luycx, Odile
    Godmer, Pascal
    Pellat-Deceunynck, Catherine
    Soussi, Thierry
    Bene, Marie C.
    Delaunay, Jacques
    Peterlin, Pierre
    HAEMATOLOGICA, 2018, 103 (04) : E143 - E146
12345